Prevalence of <scp>HIV</scp>‐1 transmitted drug resistance in the incarcerated population

Sapozhnikov, Julia; Young, J D; Patel, Mahesh C.; Chiampas, TD; Vaughn, Pyrai; Badowski, ME

doi:10.1111/hiv.12522

Cited by 5 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high (43-52%) overall DRM prevalence identified in this JI-population exceeds previous U.S. reports among other JI-populations in the U.S., which have ranged from 16-43%, [4][5][6][7] and is more similar to that from a recent analysis of a large, non-JI cohort in DC, which reported overall drug resistance of 45%. 29 Additionally, the prevalence of DRMs to InSTIs in our study population was 9%-11% which was higher than the 1.8% reported in the non-JI DC cohort study.…”

Section: Discussionsupporting

confidence: 50%

“…To date, only four U.S. studies were conducted among JI populations, at various time points in the HIV epidemic, demonstrating a wide range (16-43%) of drug resistance. [4][5][6][7] However, all these studies focused on incarcerated individuals, similar to such studies performed outside of the U.S. [8][9][10][11] To our knowledge, there have been no studies that have examined the emergence of drug resistance among persons with HIV recently released from correctional facilities.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HIV Drug Resistance and Transmission Networks Among a Justice-Involved Population at the Time of Community Reentry in Washington, D.C.

Beckwith

Min

Manne

et al. 2021

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Justice-involved (JI) populations bear a disproportionate burden of HIV infection and are at risk of poor treatment outcomes. Drug resistance prevalence and emergence, and phylogenetic inference of transmission networks, understudied in vulnerable JI populations, can inform care and prevention interventions, particularly around the critical community re-entry period. We analyzed banked blood specimens from CARE+ Corrections Study participants in Washington, D.C. (DC) across three time points and conducted HIV drug resistance testing using next-generation sequencing (NGS) at 20% and 5% thresholds to identify prevalent and evolving resistance during community re-entry. Phylogenetic analysis was used to identify molecular clusters within participants, and in an extended analysis between participants and publicly-available DC sequences. HIV sequence data from 54 participants (99 specimens) were analyzed. The prevalence of transmitted drug resistance was 14% at both thresholds, and acquired drug resistance was 47% at 20%, and 57% at 5% NGS thresholds, respectively. The overall prevalence of drug resistance was 43% at 20%, and 52% at 5% NGS thresholds, respectively. Among 34 participants sampled longitudinally, 21-35% accumulated 10-17 new resistance mutations during a mean 4.3 months. In phylogenetic analysis within the JI population, 11% were found in three molecular clusters. The extended phylogenetic analysis identified 46% of participants in 22 clusters, of which 21 also included publicly-available DC sequences, and one JI-only unique dyad. This is the first study to identify a high prevalence of HIV drug resistance and its accumulation in a JI population during community re-entry and suggests phylogenetic integration of this population into the non-JI DC HIV community. These data support the need for new, effective and timely interventions to improve HIV treatment during this vulnerable period, and for JI populations to be included in broader surveillance and prevention efforts.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Introductionmentioning

confidence: 99%

HIV Drug Resistance and Transmission Networks Among a Justice-Involved Population at the Time of Community Reentry in Washington, D.C.

Beckwith

Min

Manne

et al. 2021

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

“…In North America, data were available for pretreatment DRMs from 19,563 individuals with HIV (Supplemental Tables 18 and 19 in Additional file 1) [52,[86][87][88][89][90][91][92][93][94][95][96][97][98][99]; 6% (n=1,062/17,951) and 8% (n=1,413/17,951) had mutations resistant to the NRTI and NNRTI classes, respectively. The most frequent pretreatment 3TC/FTC DRMs were at position M184 (1%; n=216/15,401); the most frequent pretreatment RPV DRMs were at positions E138 (2%; n=5/317) and V179 (1%; n=43/6,380).…”

Section: Regional Prevalence Estimates: North Americamentioning

confidence: 99%

Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review

et al. 2018

View full text Add to dashboard Cite

Background: Pretreatment and acquired drug resistance mutations (DRMs) can limit antiretroviral therapy effectiveness. Methods: We review prevalence of DRMs with resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), focusing on lamivudine and rilpivirine, from 127 articles with >100,000 individuals with HIV-1 infection. Results: Estimated global prevalence of pretreatment resistance to any NRTI was 4% and to any NNRTI was 6%.Most prevalent DRMs resistant to lamivudine or rilpivirine were at positions E138 (4%), V179 (1%) and M184 (1%). Estimated acquired DRM prevalence was 58% for any NRTIs and 67% for any NNRTIs, most frequently at positions M184 (58%) and Y181 (21%). Conclusions: This review suggests low risk of lamivudineor rilpivirine-resistant mutations in treatment-naive, HIV-1-infected individuals.

show abstract

“…12 Penularan HIV resisten ARV juga menjadi ancaman bagi lingkungan sosial. 13 Penelitian ini adalah yang pertama kali dilakukan untuk menentukan perkiraan prevalensi HIV resisten ARV pada orang dewasa di Kabupaten Nabire, Kab/Kota Jayapura, dan Kabupaten Jayawijaya. Analisis DNA untuk mendapatkan data mutasi terkait resistensi HIV-1 terhadap ARV di Kab.…”

Section: Pendahuluanunclassified

Gambaran Kasus Mutasi Terkait Resistensi Antiretroviral pada orang dengan HIV-AIDS (ODHA) di Tiga Kabupaten/Kota di Provinsi Papua

Hutapea¹

2018

bpk

View full text Add to dashboard Cite

Antiretroviral (ARV) therapy has been found effective to decrease HIV-1 infected cases, however increase the resistances due to nucleotide mutation. The mutation causes virus to be resistant to ARV, making the therapy is no longer effective. The ARV therapy District Nabire, Jayapura, and Jayawijaya was Reverse Transcriptase Inhibitor (RTI). The goal of this study was to obtain the data of mutation associated to viral resistance to ARV RTI and protease inhibitor group. Plasma samples were obtained from 252 subjects purposively in HIV/AIDS population from corresponding Care, Support, and Therapy clinic. The genotyping, measurement of CD4 and viral load were performed to all samples. DNA analysis was performed by genotyping method. Among 252 samples, 89 samples (35.32%) had CD4 count <350 sel/ul. Twenty three samples (8.73%) had viral load >10.000 copies/mL. There were 15 (5,95%) samples were identified as mutant related to RTI resistance, and none for protease. The most frequent mutation motive was M184V/I, 12 samples (80,00%). This data provided important information about the continuous need of ARV therapy monitoring to suppress transmission drug resistance. Abstrak Penemuan antiretroviral (ARV) secara signifikan telah menjadi bagian penting dalam penanggulangan HIV/AIDS. Terapi ARV dilakukan untuk menurunkan kasus HIV-1, namun dapat menyebabkan resistensi virus terhadap ARV tersebut. Data prevalensi HIV-1 resisten ARV pada Orang Dengan HIV/AIDS (ODHA) di Papua, khususnya Kabupaten Nabire, Kab./Kota Jayapura, dan Kab. Jayawijaya belum tersedia. Tujuan penelitian ini adalah untuk mendapatkan data prevalensi mutasi terkait resistensi virus terhadap ARV golongan penghambat rtase dan protease. Sebanyak 84 responden yang sudah diterapi minimal 6 bulan diambil secara purposive dari setiap lokasi penelitian. Genotyping, pemeriksaan nilai CD4 dan viral load dilakukan terhadap semua sampel. Analisis DNA dilakukan dengan metode genotyping. Dari 252 sampel, sebanyak 89 responden (35,32%) memiliki nilai CD4 <350 sel/ul darah. Sebanyak 23 responden (8,73%) memiliki nilai viral load >10.000 salinan/mL. Sebanyak 15 sampel (5,95%) teridentifikasi mengalami mutasi pada DNA target ARV golongan penghambat rtase, dan tidak ditemukan mutasi terkait resistensi pada gen protease. Motif mutasi yang paling banyak adalah M184V/I, yaitu sebanyak 12 sampel (80,00%). Penelitian ini mengindikasikan bahwa pemantauan terapi ARV secara berkesinambungan tetap diperlukan untuk menekan penulan HIV resisten ARV.

show abstract

Prevalence of HIV‐1 transmitted drug resistance in the incarcerated population

Cited by 5 publications

References 38 publications

HIV Drug Resistance and Transmission Networks Among a Justice-Involved Population at the Time of Community Reentry in Washington, D.C.

HIV Drug Resistance and Transmission Networks Among a Justice-Involved Population at the Time of Community Reentry in Washington, D.C.

Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review

Gambaran Kasus Mutasi Terkait Resistensi Antiretroviral pada orang dengan HIV-AIDS (ODHA) di Tiga Kabupaten/Kota di Provinsi Papua

Contact Info

Product

Resources

About